Succeeder(SH:688338) Sou Hu Cai Jing·2025-08-14 13:51Core Viewpoint - The company, Saikexide, is experiencing a decline in stock price and financial performance, with a significant gap between its price-to-earnings ratio and the industry average, indicating potential undervaluation in the context of the medical device sector [1][2]. Company Summary - Saikexide's closing stock price on August 14 was 27.15 yuan, down 3.66%, with a rolling PE ratio of 27.26 times and a total market capitalization of 2.882 billion yuan [1]. - The company operates in the field of thrombus and hemostasis in vitro diagnostic instruments, reagents, and consumables, with key products including automated testing devices and various coagulation testing instruments [1]. - As of the first quarter of 2025, only one institution held shares in Saikexide, with a total of 114,800 shares valued at 0.03 million yuan [1]. - The company was recognized as a national-level specialized and innovative "little giant" enterprise in 2024 [1]. Financial Performance - In the first quarter of 2025, Saikexide reported revenue of 68.6393 million yuan, a year-on-year decrease of 9.47%, and a net profit of 23.1329 million yuan, down 23.98%, with a gross profit margin of 62.49% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Saikexide at the 54th rank within the industry [2]. - The industry shows a wide range of PE ratios, with the highest being 20.62 times for Antu Biology and the lowest at 11.18 times for Jiuan Medical [2].